Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
ADC Therapeutics
ADC Therapeutics
Activities:
Research & Development
X
LinkedIn
Trending Articles
IMPACT CKD model reveals the escalating toll of chronic kidney disease
The model projects up to 125 million of the population across eight countries to suffer from chronic kidney disease by 2032
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Isospec Analytics launches biomolecular analysis technology to identify unknown molecules
The novel technology optimises the identification process of unknown molecules compared to mass analysis
Building strong foundations for a resilient and planet-friendly future
Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI...
ten23 health and Ypsomed collaborate to commercialise the YpsoDose patch injector
The partnership will bring the drug delivery device to the pharmaceutical market quicker, whilst reducing development risks
Upcoming event
Making Pharmaceuticals
23–24 April 2024 | Exhibition | Coventry, UK
See all
Related Content
Finance
ADC Therapeutics regains compliance with NYSE continued listing standards
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs)
Ingredients
Therapeutic: loncastuximab tesirine for diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of blood cancer. Up to 40% of patients will require further lines of treatment as their disease relapses or becomes refractory to first line treatment
Pharmaceutical
FDA approves ADC supported by Sterling
ZYNLONTA has been granted accelerated approval by the FDA for use in adult patients with relapsed or refractory B-cell lymphoma (DLBCL)
Ingredients
Synaffix expands collaboration with ADC Therapeutics
ADC has expanded its existing collaboration to explore additional applications of Synaffix' site-specific conjugation technologies
Ingredients
CRT and University of Copenhagen announce agreement with ADC Therapeutics to develop antibody treatments for cancer
The antibodies target an overexpressed protein on the surface of some cancer cells, which is not expressed on healthy cells
Research & Development
ADC Therapeutics adds eight new members of staff
As the company continues to expand its pipeline of antibody drug conjugates
Research & Development
QMB welcomes ADC Therapeutics as latest tenant
Novel cancer therapy company’s arrival means QMB is almost full
Subscribe now